Ameriprise
ATHE

Ameriprise’s Alterity Therapeutics ATHE Stock Holding History

Ameriprise’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-32
Closed -$4K – 3734
2014
Q3 		$4K Buy
32
+30
+1,500% +$4.01K ﹤0.01% 5197
2014
Q2 		$0 Sell
2
-37
-95% -$4.22K ﹤0.01% 5585
2014
Q1 		$7K Hold
39
– – ﹤0.01% 4674
2013
Q4 		$16K Hold
39
– – ﹤0.01% 4159
2013
Q3 		$10K Hold
39
– – ﹤0.01% 4893
2013
Q2 		$5K Buy
+39
New +$5.29K ﹤0.01% 5124

Other funds holding ATHE

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $525M AUM 21.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Ameriprise's ATHE Position: Q4 2014 in Review

Ameriprise sold out of Alterity Therapeutics (ATHE) in Q4 2014, closing a stake of 32 shares — an estimated $4K sold.

Ameriprise first reported a position in ATHE in Q2 2013 and held it in 6 quarters. The position peaked at $16K in Q4 2013. 24 funds tracked by Wall St. Rank hold ATHE as of Q4 2014.

  • Ameriprise reported no remaining Alterity Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Ameriprise sold 32 Alterity Therapeutics shares in Q4 2014, an estimated $4K.
  • Ameriprise first reported a position in Alterity Therapeutics in Q2 2013 and held it in 6 quarters.
  • Ameriprise's Alterity Therapeutics position peaked at $16K in Q4 2013.
  • 24 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2014.

Based on Ameriprise's 13F filing for Q4 2014, filed 13 Feb 2015.